Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
Lindsey R. Baden(Brigham and Women's Hospital), Jacqueline M. Miller(Moderna Therapeutics (United States)), Hana M. El Sahly(Baylor College of Medicine), Yamuna Devi Paila(Moderna Therapeutics (United States)), Rolando Pajón(Moderna Therapeutics (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Heather Clouting(University of Maryland, Baltimore), Kathleen M. Neuzil(Center for Global Development), Gabrielle Fortier(Moderna Therapeutics (United States)), Dean Follmann(National Institute of Allergy and Infectious Diseases), Carla Talarico(Moderna Therapeutics (United States)), Allison August(University of Maryland, Baltimore), Brett Leav(University of Maryland, Baltimore), F. Schödel(St. Marianna University School of Medicine), Rituparna Das(Moderna Therapeutics (United States)), Xiaoping Zhao(Nanyang Technological University), Shu Han(Sichuan University), Weiping Deng(Yunnan Agricultural University), Brandon Essink(Velocity Clinical Research (United States)), Bethany Girard(Moderna Therapeutics (United States))
Cited by 63
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k